TCRT vs. MEIP, SLGL, BNTC, SYBX, NNVC, RNXT, GLYC, KALA, BIVI, and GLTO
Should you be buying Alaunos Therapeutics stock or one of its competitors? The main competitors of Alaunos Therapeutics include MEI Pharma (MEIP), Sol-Gel Technologies (SLGL), Benitec Biopharma (BNTC), Synlogic (SYBX), NanoViricides (NNVC), RenovoRx (RNXT), GlycoMimetics (GLYC), KALA BIO (KALA), BioVie (BIVI), and Galecto (GLTO). These companies are all part of the "pharmaceutical preparations" industry.
MEI Pharma (NASDAQ:MEIP) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.
MEI Pharma has a net margin of 39.06% compared to MEI Pharma's net margin of 0.00%. Alaunos Therapeutics' return on equity of 48.32% beat MEI Pharma's return on equity.
52.4% of MEI Pharma shares are owned by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are owned by institutional investors. 3.9% of MEI Pharma shares are owned by insiders. Comparatively, 6.2% of Alaunos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
MEI Pharma presently has a consensus price target of $7.00, indicating a potential upside of 125.44%. Given Alaunos Therapeutics' higher probable upside, analysts clearly believe MEI Pharma is more favorable than Alaunos Therapeutics.
MEI Pharma received 369 more outperform votes than Alaunos Therapeutics when rated by MarketBeat users. Likewise, 60.74% of users gave MEI Pharma an outperform vote while only 58.33% of users gave Alaunos Therapeutics an outperform vote.
MEI Pharma has higher revenue and earnings than Alaunos Therapeutics. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than MEI Pharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, MEI Pharma had 3 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 6 mentions for MEI Pharma and 3 mentions for Alaunos Therapeutics. MEI Pharma's average media sentiment score of 1.88 beat Alaunos Therapeutics' score of 0.92 indicating that Alaunos Therapeutics is being referred to more favorably in the news media.
MEI Pharma has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Alaunos Therapeutics has a beta of -0.26, meaning that its stock price is 126% less volatile than the S&P 500.
Summary
MEI Pharma beats Alaunos Therapeutics on 13 of the 15 factors compared between the two stocks.
Get Alaunos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TCRT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TCRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alaunos Therapeutics Competitors List
Related Companies and Tools
